1
|
Chu D, Qu H, Huang X, Shi Y, Li K, Lin W, Xu Z, Li D, Chen H, Gao L, Wang W, Wang H. Manganese Amplifies Photoinduced ROS in Toluidine Blue Carbon Dots to Boost MRI Guided Chemo/Photodynamic Therapy. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2024; 20:e2304968. [PMID: 37715278 DOI: 10.1002/smll.202304968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 09/04/2023] [Indexed: 09/17/2023]
Abstract
The contrast agents and tumor treatments currently used in clinical practice are far from satisfactory, due to the specificity of the tumor microenvironment (TME). Identification of diagnostic and therapeutic reagents with strong contrast and therapeutic effect remains a great challenge. Herein, a novel carbon dot nanozyme (Mn-CD) is synthesized for the first time using toluidine blue (TB) and manganese as raw materials. As expected, the enhanced magnetic resonance (MR) imaging capability of Mn-CDs is realized in response to the TME (acidity and glutathione), and r1 and r2 relaxation rates are enhanced by 224% and 249%, respectively. In addition, the photostability of Mn-CDs is also improved, and show an efficient singlet oxygen (1 O2 ) yield of 1.68. Moreover, Mn-CDs can also perform high-efficiency peroxidase (POD)-like activity and catalyze hydrogen peroxide to hydroxyl radicals, which is greatly improved under the light condition. The results both in vitro and in vivo demonstrate that the Mn-CDs are able to achieve real-time MR imaging of TME responsiveness through aggregation of the enhanced permeability and retention effect at tumor sites and facilitate light-enhanced chemodynamic and photodynamic combination therapies. This work opens a new perspective in terms of the role of carbon nanomaterials in integrated diagnosis and treatment of diseases.
Collapse
Affiliation(s)
- Dongchuan Chu
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
| | - Hang Qu
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
| | - Xueping Huang
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| | - Yu Shi
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| | - Ke Li
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| | - Wenzheng Lin
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| | - Zhuobin Xu
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| | - Dandan Li
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| | - Hao Chen
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| | - Lizeng Gao
- CAS Engineering Laboratory for Nanozyme, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China
| | - Wei Wang
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
| | - Huihui Wang
- Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, China
| |
Collapse
|
2
|
Naher HS, Al-Turaihi BAH, Mohammed SH, Naser SM, Albark MA, Madlool HA, Al- Marzoog HAM, Turki Jalil A. Upconversion nanoparticles (UCNPs): Synthesis methods, imaging and cancer therapy. J Drug Deliv Sci Technol 2023. [DOI: 10.1016/j.jddst.2023.104175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
3
|
Yan R, Liu J, Dong Z, Peng Q. Nanomaterials-mediated photodynamic therapy and its applications in treating oral diseases. BIOMATERIALS ADVANCES 2022; 144:213218. [PMID: 36436431 DOI: 10.1016/j.bioadv.2022.213218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 11/19/2022] [Accepted: 11/21/2022] [Indexed: 11/24/2022]
Abstract
Oral diseases, such as dental caries, periodontitis and oral cancer, have a very high morbidity over the world. Basically, many oral diseases are commonly related to bacterial infections or cell malignant proliferation, and usually located on the superficial positions. These features allow the convenient and efficient application of photodynamic therapy (PDT) for oral diseases, since PDT is ideally suitable for the diseases on superficial sites and has been widely used for antimicrobial and anticancer therapy. Photosensitizers (PSs) are an essential element in PDT, which induce the generation of a large number of reactive oxygen species (ROS) upon absorption of specific lights. Almost all the PSs are small molecules and commonly suffered from various problems in the PDT environment, such as low solubility and poor stability. Recently, reports on the nanomedicine-based PDT have been well documented. Various functionalized nanomaterials can serve either as the PSs carriers or the direct PSs, thus enhancing the PDT efficacy. Herein, we aim to provide a comprehensive understanding of the features of different oral diseases and discuss the potential applications of nanomedicine-based PDT in the treatment of some common oral diseases. Also, the concerns and possible solutions for nanomaterials-mediated PDT are discussed.
Collapse
Affiliation(s)
- Ruijiao Yan
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
| | - Jianhong Liu
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
| | - Zaiquan Dong
- Mental Health Center of West China Hospital, Sichuan University, Chengdu 610041, China.
| | - Qiang Peng
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
| |
Collapse
|